Thorax 59 , 120125 (2004)
Type 2 Diabetes and MASH Research Separate Phase 2 trials have evaluated retatrutide in participants with type 2 diabetes, where it demonstrated excellent glycemic control with substantial HbA1c reductions (mean reductions of 1.8-2.0% from baselines around 8%), along with impressive weight loss similar to that seen in non-diabetic participants
20 118 [66.1%] female), with 14 101 undergoing MBS (mean [SD] follow-up, 34 [16] months) and 16 357 receiving GLP-1 RAs (mean [SD] follow-up, 32 [17] months)
He is an Associate Professor at the Uniformed Services University of the Health Sciences, Bethesda, MD with research interests in dermatopharmacology, clinical pharmacology, clinical study design and endpoints assessment (including patient-reported outcomes) for medical, surgical, and aesthetic products